At the IDWeek 2023 infectious disease conference, Rachelle Koch, a medical student from the University of Texas Southwestern Medical Center, presented the work done in David Greenberg’s Lab on a new strategy to tackle Pseudomonas aeruginosa infections using D-peptide-conjugated phosphorodiamidate morpholino oligomers (D-PPMOs). P. aeruginosa is an opportunistic pathogen showing a multidrug-resistance (MDR) pattern that is at the root of significant morbidity and mortality, especially in immunocompromised patients with severe chronic lung diseases such as cystic fibrosis. Read More
Researchers from Shanghai Henlius Biotech Inc. presented the discovery and preclinical characterization of HLX-42, a next-generation EGFR-targeting antibody-drug conjugate (ADC) being developed for the treatment of cancer. Read More
Researchers from Centessa Pharmaceuticals plc presented the preclinical characterization of ORX-750, a novel selective orexin receptor 2 (OX2R) agonist aimed to be used for the treatment of narcolepsy. Read More
Viridian Therapeutics Inc. has disclosed a preclinical portfolio of neonatal Fc receptor (FcRn) inhibitors designed for next-generation treatment of antibody-mediated autoimmune diseases. Read More
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed HER2 (erbB2) and/or HER2 (erbB2) mutant inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from Biontech SE and Genmab BV presented the discovery and preclinical evaluation of a novel Duobody-EpCAMx4-1BB (BNT314/GEN1059), a novel Fc-inert immunomodulatory bispecific antibody (bsAb) designed to boost antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity. Read More
Sparx Biopharmaceutical Corp. has received FDA approval of its IND application for SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody drug candidate. Read More
Researchers from Coave Therapeutics SA presented a novel conjugated AAV (coAAV)-GBA1 candidate for the treatment of patients suffering from PD related to GBA1 mutations. Read More
Bial-Portela & CA SA has synthesized water-soluble phosphate prodrugs of opicapone reported to be useful for the treatment of Parkinson's disease. Read More
Nerviano Medical Sciences Srl has identified cyclin-dependent kinase 11A (CDK11A) inhibitors reported to be useful for the treatment of cancer and immunological disorders. Read More
Aquinnah Pharmaceuticals Inc. has announced preclinical research findings for a novel small-molecule therapeutic designed to slow or stop the progression of Alzheimer's disease and related disorders. Read More
Denali Therapeutics Inc. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer's disease, atherosclerosis, asthma, nonalcoholic fatty liver disease (NAFLD), multiple sclerosis (MS), experimental autoimmune encephalitis, type 1 diabetes and rheumatoid arthritis, among others. Read More
Chimeric Therapeutics Ltd. has received FDA clearance of its IND application for CHM-2101, a first-in-class CDH17 chimeric antigen receptor (CAR) T cell therapy for gastrointestinal (GI) cancers. Read More
Prelude Therapeutics Inc. has described phosphatidylinositol 3-kinase α (PI3Kα) (His1047Arg mutant) inhibitors reported to be useful for the treatment of cancer and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities. Read More
